serine has been researched along with homoharringtonine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Han, CS; Huang, CC; Shen, CM; Wang, SW; Wu, FG; Xu, B; Yue, XF | 1 |
| Chen, J; Gan, X; Gan, Y; Gu, Y; Huang, W; Li, H; Liang, Y; Lu, X; Ma, X; Meng, Z; Wang, X; Xu, G; Xu, R; Xu, X; Zhang, J; Zhang, X; Zheng, W; Zhou, H | 1 |
| Cheng, YS; Chien, CY; Chung, YH; Hsieh, CH; Hsu, CH; Hsu, WM; Huang, CT; Huang, HC; Juan, HF; Lee, YH; Liu, YL; Yang, TS | 1 |
3 other study(ies) available for serine and homoharringtonine
| Article | Year |
|---|---|
Cytotoxicity and sister chromatid exchanges induced in vitro by six anticancer drugs developed in the People's Republic of China.
Topics: Alkaloids; Amaryllidaceae Alkaloids; Amino Acids, Dicarboxylic; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cell Line; China; Cricetinae; Cricetulus; Crossing Over, Genetic; Harringtonines; Homoharringtonine; Humans; Indolizines; Lung; Lymphoid Tissue; Mutagenicity Tests; Serine; Sister Chromatid Exchange | 1983 |
Small-molecule induction of phospho-eIF4E sumoylation and degradation via targeting its phosphorylated serine 209 residue.
Topics: Acute Disease; Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Line, Tumor; Dose-Response Relationship, Drug; Eukaryotic Initiation Factor-4E; Harringtonines; Homoharringtonine; Humans; Interleukin Receptor Common gamma Subunit; Leukemia, Myeloid; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Molecular Structure; Phosphorylation; Proteasome Endopeptidase Complex; Protein Multimerization; Proteolysis; Serine; Small Ubiquitin-Related Modifier Proteins; Sumoylation; Tumor Cells, Cultured; Ubiquitins; Xenograft Model Antitumor Assays | 2015 |
Homoharringtonine as a PHGDH inhibitor: Unraveling metabolic dependencies and developing a potent therapeutic strategy for high-risk neuroblastoma.
Topics: Child; Enzyme Inhibitors; Homoharringtonine; Humans; Molecular Docking Simulation; Neuroblastoma; Phosphoglycerate Dehydrogenase; Serine | 2023 |